Evidence map›Paper›PMID 23328585›Full record

ArticleCancer research2013

Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model.

Sunitha V Bachawal, Kristin C Jensen, Amelie M Lutz, Sanjiv S Gambhir, Francois Tranquart, Lu Tian, Jürgen K Willmann

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular Ultrasound Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  4. Article
  5. Review
  6. Acoustic Molecular Imaging Beyond the Diffraction Limit In Vivo.IEEE open journal of ultrasonics, ferroelectrics, and frequency control · 2022
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Molecular Ultrasound Imaging.Nanomaterials (Basel, Switzerland) · 2020
    Review
  12. Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sunitha V BachawalDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA.
Kristin C Jensen
Amelie M Lutz
Sanjiv S Gambhir
Francois Tranquart
Lu Tian
Jürgen K Willmann
Bracco (Switzerland) · CHVA Palo Alto Health Care System · USStanford University · US

Funding

Molecular Ultrasound for Early Breast Cancer DetectionR01CA155289 · NCI · STANFORD UNIVERSITY · PI WILLMANN, JUERGEN KARL · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA155289NCI NIH HHS R01 CA155289-01A1
6 · The paper itself

Abstract

While there is an increasing role of ultrasound for breast cancer screening in patients with dense breast, conventional anatomical ultrasound lacks sensitivity and specificity for early breast cancer detection. In this study, we assessed the potential of ultrasound molecular imaging using clinically translatable vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted microbubbles (MB(VEGFR2)) to improve the diagnostic accuracy of ultrasound in earlier detection of breast cancer and ductal carcinoma in situ (DCIS) in a transgenic mouse model [FVB/N-Tg(MMTV-PyMT)634Mul]. In vivo binding specificity studies (n = 26 tumors) showed that ultrasound imaging signal was significantly higher (P < 0.001) using MB(VEGFR2) than nontargeted microbubbles and imaging signal significantly decreased (P < 0.001) by blocking antibodies. Ultrasound molecular imaging signal significantly increased (P < 0.001) when breast tissue (n = 315 glands) progressed from normal [1.65 ± 0.17 arbitrary units (a.u.)] to hyperplasia (4.21 ± 1.16), DCIS (15.95 ± 1.31), and invasive cancer (78.1 ± 6.31) and highly correlated with ex vivo VEGFR2 expression [R(2) = 0.84; 95% confidence interval (CI), 0.72-0.91; P < 0.001]. At an imaging signal threshold of 4.6 a.u., ultrasound molecular imaging differentiated benign from malignant entities with a sensitivity of 84% (95% CI, 78-88) and specificity of 89% (95% CI, 81-94). In a prospective screening trail (n = 63 glands), diagnostic performance of detecting DCIS and breast cancer was assessed and two independent readers correctly diagnosed malignant disease in more than 95% of cases and highly agreed between each other [intraclass correlation coefficient (ICC) = 0.98; 95% CI, 97-99]. These results suggest that VEGFR2-targeted ultrasound molecular imaging allows highly accurate detection of DCIS and breast cancer in transgenic mice and may be a promising approach for early breast cancer detection in women.

Indexed as

AnimalsBreast NeoplasmsDisease ProgressionFemaleMiceMice, TransgenicProtein BindingUltrasonographyVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2

Identifiers

PMID23328585
PMCPMC3602408
OpenAlexW2128341099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.